What do you do if you are an innovative but small “David” of an allergy nasal spray that has to do battle with a “Goliath”—in this case, an iconic bee? If you’re the Omnaris team at Sepracor, you ...
Treatment of seasonal allergic rhinitis in patients ≥6 years old and perennial allergic rhinitis in patients ≥12 years old. Omnaris is an alcohol-free, hypotonic suspension formulation of the ...
In a large-scale Phase III study, OMNARIS delivered in an aerosol nasal formulation propelled by HFA (hydrofluoroalkane) met both its primary and key secondary endpoints MARLBOROUGH, Mass., Apr 27, ...
Omnaris available for allergy treatment Omnaris (ciclesonide nasal spray, from Sepracor) is now available for the treatment of nasal symptoms associated with seasonal allergic rhinitis in patients ≥6 ...
Data Presented at ACAAI Builds Upon Sunovion Legacy in Respiratory Therapies MARLBOROUGH, Mass., Saturday, November 5, 2011 - Sunovion Pharmaceuticals Inc. (Sunovion) today announced results from a ...
Altana of Germany has won an important new drug approval in the USA for Omnaris, a new corticosteroid nasal spray for seasonal and perennial allergic rhinitis that is tipped as a major new product for ...
Nasal allergy medicines can leave you slow and sleepy. Not only that, but many smell or taste funny. Amid many medications, Omnaris is a smell-free, taste-free, alcohol-free product. With many ...
The Global Ciclesonide Market, by Indication (Allergic Rhinitis and Asthma), by Dosage Form (Nasal Spray and Aerosol), and by Region (North America, Asia Pacific, Latin America, Europe, Middle East, ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has entered into a definitive agreement to divest the U.S. market rights to Sunovion’s ciclesonide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results